 |
 |
PharmaVOICE - September 2009 Patient Recruitment: Strategies for Multinational Studies By Denise Myshko Finding appropriate study subjects is still one of the biggest stumbling blocks for timely and efficient drug development. Recruiting patients for multinational trials can be even more daunting, since global trials add to the complexity. While experts say some issues are no longer an obstacle — such as technology infrastructure or finding trained investigators in many regions — multinational studies still present a challenge. A Cutting Edge Information study, Clinical Outsourcing Strategy, reports that patient enrollment is often underfunded and under-resourced. And according to Cutting Edge’s Streamlining Clinical Trials study, patient recruitment accounts for about 23% of the total clinical development timeline... Sidebar: Physician Referral Study 10 Cost-Saving Strategies for Patient Recruitment and Retention Experts on this topic Gaynor Anders. VP, Global Operations, MMG, a full-service patient recruitment and retention group. For more information, visit wegetpatients.com. Ubavka Denoble, M.D. Senior VP, Global Project Management, i3 Research, a therapeutically specialized, global clinical research organization. For more information, visit i3global.com. Peter A. DiBiaso. Senior Clinical Operations Director, Shire Pharmaceuticals, a specialty biopharmaceutical company. For more information, visit shire.com. Roberta Duncan. Global Service Head, Site Start-up Management, Kendle, a global full-service clinical research organization. For more information, visit kendle.com. Ran Frenkel, R.Ph. CEO, Pharma Focus Israel, an international research management organization that addresses the limitations of conventional study practices. For more information, visit pharmafocus.co.il. Matt Kibby. Director, Global Operations, BBK Worldwide, a patient recruitment consultation and implementation partner. For more information, visit bbkworldwide.com. Rick Malcolm. CEO, Acurian Inc., a full-service provider of clinical trial patient recruitment solutions for the life-sciences industry. For more information, visit acurian.com. Joel Z. Melnick, M.D. VP, Clinical Research and Development, Cytochroma Inc., a clinical-stage specialty pharmaceutical company focused on products to treat and prevent vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease. For more information, visit cytochroma.com. Elizabeth Moench. President and Founder, MediciGlobal, a specialty patient recruitment-retention firm serving the clinical trials industry. For more information, visit mediciglobal.com.
|
